- In March 2026, QIAGEN N.V. reported new clinical and health economic data showing its QuantiFERON-TB Gold Plus blood test improved tuberculosis infection detection and reduced modeled lifetime healthcare costs versus the tuberculin skin test, especially in immunocompromised and other high-risk patients.
- The findings, alongside more than 2,500 supporting studies and over 125 million tests used worldwide, highlight QuantiFERON’s role in earlier preventive treatment and more efficient resource use as QIAGEN advances next-generation assays and AI-supported risk prediction.
- We’ll now examine how this expanded clinical and economic evidence base for QuantiFERON-TB Gold Plus could influence Qiagen’s broader investment narrative.
AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Qiagen Investment Narrative Recap
To own Qiagen, you need to believe its molecular diagnostics and TB testing franchises can keep gaining clinical relevance and recurring consumables use, even as research and China markets stay uneven. The new QuantiFERON-TB Gold Plus data deepens that franchise’s clinical and economic credibility, but does not fundamentally change the nearer term focus on QIAstat-Dx uptake and macro pressures on margins.
Among recent developments, the US FDA clearance of the high throughput QIAstat-Dx Rise system for GI panels looks especially important, as it reinforces Qiagen’s push into automated, scalable syndromic testing that could offset softer instrument demand elsewhere.
Yet, even with growing clinical validation, investors should be aware that intensifying competition in digital PCR and syndromic testing could...
Read the full narrative on Qiagen (it's free!)
Qiagen's narrative projects $2.5 billion revenue and $606.9 million earnings by 2029. This requires 6.1% yearly revenue growth and a $182.0 million earnings increase from $424.9 million today.
Uncover how Qiagen's forecasts yield a $55.46 fair value, a 42% upside to its current price.
Exploring Other Perspectives
Four Simply Wall St Community fair value estimates span from about US$55 to above US$96,000 per share, showing how far opinions can stretch. Set this against Qiagen’s reliance on expanding QIAstat-Dx adoption as a key growth pillar and you can see why it pays to compare several independent views before forming your own stance.
Explore 4 other fair value estimates on Qiagen - why the stock might be worth just $55.46!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Qiagen research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
- Our free Qiagen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Qiagen's overall financial health at a glance.
Seeking Other Investments?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- Find 62 companies with promising cash flow potential yet trading below their fair value.
- The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com